kaiser permanente glp-1 coverage news drugs present an uncertain opportunity for healthcare GLP1 NEWS: Medicare Part D

In two studies with adults who had obesity and moderate to severe OSA over a 52-week period, participants who received Zepbound experienced a "statistically significant and clinically meaningful reduction" in episodes of shallow breathing or temporary pauses in breathing while asleep compared to those who received a placebo, the FDA said

I think menopause should be optional

Theyre likely to be taking these drugs for shorter durations, so any consumer-facing company thats adjusting product and marketing strategies in response to the rise in usage rates were seeing for these drugs should also be taking into account that a larger underlying user base means that we'll be seeing a growing number of consumers who are also stopping and ceasing these drugs over time as well. How To Respond In addressing how retailers and food and beverage companies should respond, Circana said that while some consumers will resume their pre-GLP-1 purchase habits when they cease treatment, for many others, varying forms of the medication, supplements and CPG food and beverage will play critical roles in how individuals manage their conditions. Some areas of opportunity include: Product innovation: Develop and promote products that align with the dietary needs of GLP-1 users, Circana said

Systemic corticosteroids became necessary for treating severe cases of injection-site reactions, which typically would resolve on their own

Short-acting and long-acting preparations of GLP-1RA have distinct effects on controlling blood sugar (58)

So weve got two that I think primetime that being on label use and maybe for psychotropic drug weight gain